# Quantum Bio Recovery Engine — Lab Journal

## Researcher
Rishabh Kumar  
Frontend & Full-Stack Engineer | Quantum-Bio Systems Researcher (Independent)

## Start Date
16 January 2026

## Time Commitment
4–5 hours per day (consistent long-term research cadence)

---

## 1. Motivation

This project is driven by a personal and scientific mission: to build a computational system that can simulate how drugs influence complex biological systems at the level of protein networks, not just individual molecular targets.

Rather than asking:
> "Does this drug bind to this protein?"

This work asks:
> "Does this drug move a diseased biological system closer to a healthy state, and with what probability?"

This approach combines systems biology, artificial intelligence, probabilistic modeling, and quantum optimization to explore drug discovery and therapeutic evaluation as a multi-scale, dynamic problem.

---

## 2. Long-Term Vision

The long-term vision is to develop a hybrid AI–Quantum platform capable of:

- Modeling healthy and diseased protein interaction networks
- Simulating drug-induced perturbations across biological pathways
- Estimating the probability of therapeutic success and systemic risk
- Supporting both open scientific research and real-world translational applications

This system is designed to be:
- Publishable in peer-reviewed scientific venues
- Reproducible by independent researchers
- Extensible into a clinical or pharmaceutical research platform

---

## 3. Core Hypothesis

A hybrid quantum–classical optimization framework can improve the accuracy and robustness of drug efficacy prediction by:

- Finding lower-energy, more stable drug–protein binding conformations
- Optimizing network-level biological state transitions toward healthy reference states
- Integrating probabilistic inference over molecular, network, and clinical priors

Compared to classical docking and scoring alone, this approach should yield higher-quality candidate ranking and more meaningful system-level predictions.

---

## 4. Flagship Disease Model

**Proposed Disease:** Multiple Sclerosis (MS)

**Rationale:**
- Rich, publicly available protein interaction and gene expression datasets
- Well-characterized immune, neural, and metabolic pathways
- Multiple existing FDA-approved drugs for benchmarking
- Strong relevance to neurological systems and network-level dysfunction

This disease model will serve as the primary reference system for development, benchmarking, and publication.

---

## 5. System Architecture (High-Level)

```
Disease / Protein Set
↓
Protein Interaction Network (Healthy vs Diseased)
↓
Drug Input (SMILES / Known Compounds)
↓
Classical Docking & Pre-Filtering
↓
Quantum Optimization Layer
↓
Systems-Level Network Simulation
↓
Bayesian Probability Engine
↓
Therapeutic Success & Risk Scores
```


---

## 6. Scientific Principles

This work draws from:

- Network Medicine (Barabási et al.)
- Quantum Chemistry and Variational Algorithms
- Bayesian Inference and Probabilistic Graphical Models
- Graph Neural Networks and Systems Biology
- Open Science and Reproducible Research Practices

---

## 7. Milestones

### Phase 1 — Biological Network Engine
- Build healthy and diseased protein interaction networks
- Define system distance and recovery metrics

### Phase 2 — Chemical Interaction Layer
- Implement molecular docking and binding score extraction
- Integrate ADMET prediction

### Phase 3 — Quantum Optimization
- Encode binding and network energy functions as Hamiltonians
- Apply VQE / QAOA for optimization

### Phase 4 — Probability & Validation
- Build Bayesian success/risk estimation
- Benchmark against classical pipelines
- Prepare publication-quality results

---

## 8. Open Science Commitment

This project will prioritize:
- Transparent methods
- Reproducible experiments
- Open-source core components
- Public benchmarks and documentation

Sensitive datasets, enterprise integrations, and scalable infrastructure layers may remain proprietary in later translational phases.

---

## 9. Weekly Reflection Log

### Week 1 — Foundation
**Goal:** Build protein network model for MS and define system state metrics.

Reflections:

###### Week 1 — Foundation (Reflection Entry)

```
MS Reference Network v1
Successfully constructed a 10-node, 35-edge high-confidence protein–protein interaction (PPI) network for Multiple Sclerosis using STRING DB. The network exhibits high density and reveals IFNG as a dominant hub, consistent with immune-centric system architecture reported in MS pathology. This validated both the biological relevance of the selected protein set and the integrity of the network construction pipeline.

This reference network will serve as the baseline system state for subsequent drug perturbation modeling, healthy vs diseased state comparison, and probabilistic recovery scoring.
```

```
Implemented disease state modeling by integrating gene expression fold-change data into the MS PPI network as node activity weights. Defined a cosine-based system distance metric to quantify deviation between healthy and diseased biological states, establishing a numerical baseline for future drug-induced recovery scoring.
```

```
Upgraded disease distance metric to incorporate edge-weighted interaction strength, transforming the system model from node-only perturbation to network-aware disruption scoring. This better reflects hub-driven pathology characteristic of immune-mediated diseases such as MS.
```

```
Upgraded system distance metric to a network-aware, edge-weighted formulation. Resulting MS disease score (~1.27) reflects hub-amplified immune and neuroinflammatory disruption, consistent with known MS pathology. This scalar function now serves as a candidate system “energy” for optimization and therapeutic recovery modeling.
```

```
Implemented network-level drug perturbation modeling using a target-weighted effect vector. Fingolimod simulation produced a recovery score of ~0.45, indicating partial restoration of immune-neuro system state consistent with known disease-modifying (non-curative) clinical behavior in MS. This validates the system’s ability to produce qualitatively realistic therapeutic response patterns.
```

```
Implemented a Bayesian success model mapping network-level recovery scores into probabilistic therapeutic success estimates using a Beta posterior with Monte Carlo uncertainty. This transforms deterministic system recovery metrics into confidence-bounded decision variables suitable for drug ranking and trial prioritization.
```

```
Implemented Bayesian probability mapping of network recovery scores. Fingolimod produced a moderate success probability (mean ≈ 0.41, 95% CI ≈ 0.26–0.58), reflecting cautious inference under weak priors and injected uncertainty. This demonstrates the system’s ability to express therapeutic predictions with calibrated confidence rather than deterministic scores.
```

```
Executed a multi-drug virtual screening pipeline for MS. Fingolimod ranked highest (Recovery ≈ 0.63, P ≈ 0.67, 95% CI ≈ 0.54–0.79), indicating strong system-wide immune network stabilization. Dimethyl fumarate showed moderate efficacy, while Natalizumab and Interferon-beta exhibited weaker system-level recovery, reflecting narrower mechanistic impact. Results support the value of network-centric therapeutic prioritization over single-target scoring.
```

```
Executed a pairwise combination therapy synergy analysis across the MS protein interaction network. Identified Fingolimod + Dimethyl Fumarate as the top synergistic combination (Recovery ≈ 0.88, Synergy ≈ 0.25, P ≈ 0.87, 95% CI ≈ 0.77–0.95), indicating complementary stabilization of immune and neuroinflammatory network hubs. Results demonstrate the platform’s capacity to discover emergent multi-target therapeutic effects beyond single-agent efficacy.
```

```
Validated the drug-combination Hamiltonian using an exact minimum eigensolver. The optimizer independently identified Fingolimod + Dimethyl Fumarate as the optimal combination (objective ≈ 1.261), matching network-level synergy and probabilistic screening results. This confirms internal consistency across biological modeling, probabilistic inference, and optimization layers, establishing a reproducible benchmark for future quantum and heuristic solvers.
```

```
Initial scaling benchmarks for k=2 combinations showed identical performance across exact, greedy, and random solvers, confirming polynomial-time tractability for pairwise optimization. This establishes a baseline regime and motivates extension to higher-order (k≥3) combination selection to enter the combinatorial hardness domain relevant for quantum-assisted optimization.
```

```
Scaling benchmarks for k=3 revealed the onset of heuristic failure at N ≥ 12, where greedy selection exhibited measurable optimality gaps relative to the exact Hamiltonian solver, while random search performance became trial-dependent. This identifies a transition into a combinatorial hardness regime suitable for evaluating hybrid quantum–classical optimization approaches.
```

```
Demonstrated combinatorial scaling in k=4 therapeutic combination optimization, with exact Hamiltonian solver runtime increasing by >500× between N=8 and N=24, while heuristic methods remained constant-time but developed measurable optimality gaps. This establishes a hardness regime suitable for evaluating hybrid quantum–classical optimization approaches.
```

---

## 10. Signature

I commit to building this system with scientific integrity, long-term discipline, and the intent to contribute meaningful tools and knowledge to the global research and medical community.

**Signed:**  
Rishabh Kumar  
**Date:** 16 January 2026
